470 million! Kyusju Tong has another big move

state drug control covers the largest number of level 3 hospitals, and Kyushua Tong in the county-level network has an advantage, if the new crown vaccine vaccination sinks to the grass-roots level, Kyushua Tong will get more revenue.

signed a total of 472 millionOn January 21, Kyushua Tong Pharmaceutical Group Co., Ltd. (hereinafter referred to as Kyushua Tong) and the Asian Development Bank (hereinafter referred to as ADB) and Germany Investment and Development Co., Ltd. (hereinafter referred to as Germany) signed a long-term loan agreement, and ADB and Germany issued a private sector loan of 60 million euros (a total of 472 million yuan) to expand Kyushua Tong's pharmaceutical logistics center.It is understood that the loan is intended to focus on Haikou City, Hainan Province, Tangshan City, Hebei Province and Nanjing City, Jiangsu Province, the construction and expansion of cold chain storage facilities, especially the construction, transformation and improvement of cold chain logistics facilities, will better improve the Kyushua-related vaccine and other cold chain biological products storage, distribution and service capacity.In addition, Kyushua said: the most important measure to combat the new crown epidemic is to vaccinate the new crown vaccine, Kyushua to give full play to their advantages in the national cold chain logistics distribution and distribution, storage, system management and operation, the near-term focus on vaccine cold chain distribution services.Because this year's special circumstances have decided that once a vaccine is developed, vaccinations around the world must be promoted in order to be truly immune. In the case of repeated epidemic prevention at home and abroad, vaccine research and development and supporting facilities are the focus of social concern, in 2019 China's vaccine field issued a number of 580 million, this year's special circumstances brought about by the increase in the number of vaccines in 2.8-42 billion.To some extent, the outbreak is a special event, if with the arrival of vaccines, the outbreak improves, vaccine demand declines, Kyusju Tong plans to invest in the vaccine cold chain storage facilities will be how to deal with?In response to a question from Sebalan, Liu Zhaoying, vice chairman of Kyushua Tong, said: In order to meet the distribution of the new crown vaccine, Kyushua Tong has invested a lot of money - such as buying vehicles, hiring drivers, improving systems and operations, plus improving storage facilities in the cold chain.These investments will also follow the trend to increase Kyusju Tong's business layout in the field of biomedicine.Today, the demand for cold-chain logistics and distribution in biopharmaceuticals is growing year by year, including the need for cold-chain storage facilities and transportation for some testing reagents, Liu said. As a result, after the subsequent outbreak improves and vaccine demand declines, Kyusju Tong will transfer the new facilities to other biological products and vaccine products that require cold chains for transportation and storage.

to increase the business layout of biopharmaceuticalsAccording to EvaluatePharma, global biopharmaceas sales have grown from $129 billion in 2010 to $243 billion in 2018, with a compound annual growth rate of 8.24%, well above the 0.45% of traditional drugs, and the share of global drug sales has increased rapidly from 18% in 2010 to 28% in 2018.Data show that China's biopharmaceutical market is still in the early stages of development, but has strong growth potential, the growth rate is ahead of the pharmaceutical market as a whole. In 2018, China's biopharmace products market reached RMB262.2 billion. China's biopharmaceonceon market is expected to expand further to RMB641.2 billion by 2023, with a compound annual growth rate of 19.6% over the same period, as affordability increases, patient population growth, and expanded health insurance coverage. As investment in pharmaceutical research and development increases, the biopharmaceutical market is expected to reach RMB1,319.8 billion in 2030, with a compound annual growth rate of 10.9% from 2023 to 2030.The rapid growth of biopharmaceons has also accelerated its demand for cold chain transportation.Industry insiders told the financial sector that China's biomedical cryogenic storage market industry growth rate is higher than the global (4.1%), under the new crown vaccine catalytic, cold chain transport industry development is expected to speed up, and hundreds of millions of doses of calculated new crown vaccine, to the cold chain market to bring huge imagination space.To a certain extent, with the vigorous development of biopharmaceutical enterprises, the further expansion of national support in the future, the market demand for cold chain logistics will also increase, so whether enterprises can use cold chain transport pharmaceutical products, whether the cold chain logistics qualifications put forward higher requirements.It is worth noting that the transportation and preservation of pharmaceutical preparations has high professional requirements, especially vaccine products, need to have a very strong cold chain storage infrastructure support, which is often difficult to achieve ordinary logistics storage and cold chain, which is also rich in cold chain logistics experience Kyusju Tong advantages. How can Kyusju Tong benefit from the surge in cold chain demand? It is understood that vaccine products, injection needles, antidoctures, oral drugs, foreign medicines, blood products and other pharmaceutical refrigeration products sales amount accounted for about 10% of the total sales of China's pharmaceutical circulation enterprises, the market space is huge. The increase in vaccines brought about by the outbreak was superimposed, and demand for the pharmaceutical cold chain surged. Data show that the market size of China's pharmaceutical cold chain industry grew from RMB750 million in 2013 to RMB1.24 billion in 2017, with a compound annual growth rate of 13.3%. According to the Panther Research Institute, the market size of China's pharmaceutical cold chain industry will reach 2.97 billion yuan by 2022. Today, many enterprises have seen the pharmaceutical cold chain business opportunities and market potential - not only the main business for the pharmaceutical cold chain enterprises to enter the market, but also a third-party logistics enterprises involved, and has a greater competitiveness. Shunfeng, for example, and in 2016 set up a "cold transport division", the main line of medicine transport network currently covers 26 major cities in China, regional distribution covers 26 major cities around the 200 km area. At the same time, the state control, medicine, China Resources, Kyushua and other pharmaceutical circulation enterprises have been deployed in the pharmaceutical cold chain distribution business. Data show that Kyusju Tong company and its molecular companies to carry out pharmaceutical cold chain business has more than 20 years of history, has a wealth of cold storage resources, a total of 455 GSP cold storage, cold storage capacity of 105,000 m3, the accuracy of the storage reached 99.999%. In addition, Kyuswa Tong has more than 250 refrigerated trucks and more than 5000 insulation boxes and other facilities and equipment, the company since 2014, set up a professional cold chain business division, the formation of more than 50 people of the pharmaceutical cold chain professional operation team, is committed to vigorously develop cold chain business. According to Kyusju Tong's 2019 annual report, the company's cold chain support business in 2019 tax-inclusive sales of more than 3.6 billion yuan. Compared with China National Pharmaceutical Holdings, it currently has 15 years of operating experience of the national medicine consistent, with more than 7000 medical cold storage, medicine refrigeration vehicles nearly 60. From the terminal coverage point of view, the state drug control covers the largest number of three-level hospitals, and Kyushua Tong in the county-level network has an advantage, if the new crown vaccine vaccination sinks to the grass-roots level, Kyushua Tong will get more revenue.  As Kyusju Tong said: the construction of cold chain logistics facilities, which will ensure that Kyusju Tong better serve China's second- and third-tier cities and rural areas, including the broader population of emergency supplies of medical supplies will play an important role. (Cypress Blue)